110 related articles for article (PubMed ID: 32826057)
1. Osteoblastic differentiation of bone marrow mesenchymal stem cells in uremic rats.
Kato T; Mizobuchi M; Sasa K; Yamada A; Ogata H; Honda H; Sakashita A; Kamijo R
Biochem Biophys Res Commun; 2020 Oct; 532(1):11-18. PubMed ID: 32826057
[TBL] [Abstract][Full Text] [Related]
2. Differential effects of vitamin D receptor activators on aortic calcification and pulse wave velocity in uraemic rats.
Noonan W; Koch K; Nakane M; Ma J; Dixon D; Bolin A; Reinhart G
Nephrol Dial Transplant; 2008 Dec; 23(12):3824-30. PubMed ID: 18644798
[TBL] [Abstract][Full Text] [Related]
3. Bone elongation in rats with renal failure and mild or advanced secondary hyperparathyroidism.
Sanchez CP; He YZ; Leiferman E; Wilsman NJ
Kidney Int; 2004 May; 65(5):1740-8. PubMed ID: 15086913
[TBL] [Abstract][Full Text] [Related]
4. Up-regulation of Cbfa1 and Pit-1 in calcified artery of uraemic rats with severe hyperphosphataemia and secondary hyperparathyroidism.
Mizobuchi M; Ogata H; Hatamura I; Koiwa F; Saji F; Shiizaki K; Negi S; Kinugasa E; Ooshima A; Koshikawa S; Akizawa T
Nephrol Dial Transplant; 2006 Apr; 21(4):911-6. PubMed ID: 16384827
[TBL] [Abstract][Full Text] [Related]
5. Etelcalcetide (AMG 416), a peptide agonist of the calcium-sensing receptor, preserved cortical bone structure and bone strength in subtotal nephrectomized rats with established secondary hyperparathyroidism.
Li X; Yu L; Asuncion F; Grisanti M; Alexander S; Hensley K; Han CY; Niu QT; Dwyer D; Villasenor K; Stolina M; Dean C; Ominsky MS; Ke HZ; Tomlinson JE; Richards WG
Bone; 2017 Dec; 105():163-172. PubMed ID: 28867373
[TBL] [Abstract][Full Text] [Related]
6. Effect of sevelamer hydrochloride on bone in experimental uremic rats.
Kuwahara M; Inoshita S; Terada Y; Sasaki S
Ther Apher Dial; 2009 Feb; 13(1):42-8. PubMed ID: 19379169
[TBL] [Abstract][Full Text] [Related]
7. Dietary Changes Involving Bifidobacterium longum and Other Nutrients Delays Chronic Kidney Disease Progression.
Iwashita Y; Ohya M; Yashiro M; Sonou T; Kawakami K; Nakashima Y; Yano T; Iwashita Y; Mima T; Negi S; Kubo K; Tomoda K; Odamaki T; Shigematsu T
Am J Nephrol; 2018; 47(5):325-332. PubMed ID: 29779028
[TBL] [Abstract][Full Text] [Related]
8. Bone marrow stromal cells from low-turnover osteoporotic mouse model are less sensitive to the osteogenic effects of fluvastatin.
Oda Y; Sasaki H; Miura T; Takanashi T; Furuya Y; Yoshinari M; Yajima Y
PLoS One; 2018; 13(8):e0202857. PubMed ID: 30142209
[TBL] [Abstract][Full Text] [Related]
9. The effects of sevelamer hydrochloride and calcium carbonate on kidney calcification in uremic rats.
Cozzolino M; Dusso AS; Liapis H; Finch J; Lu Y; Burke SK; Slatopolsky E
J Am Soc Nephrol; 2002 Sep; 13(9):2299-308. PubMed ID: 12191974
[TBL] [Abstract][Full Text] [Related]
10. Correction of hyperphosphatemia suppresses cardiac remodeling in uremic rats.
Yamazaki-Nakazawa A; Mizobuchi M; Ogata H; Kumata C; Kondo F; Ono N; Koiwa F; Uda S; Kinugasa E; Akizawa T
Clin Exp Nephrol; 2014 Feb; 18(1):56-64. PubMed ID: 23740131
[TBL] [Abstract][Full Text] [Related]
11. Expression of bone type 1 PTH receptor in rats with chronic renal failure.
Kuwahara M; Inoshita S; Nakano Y; Terada Y; Takano Y; Sasaki S
Clin Exp Nephrol; 2007 Mar; 11(1):34-40. PubMed ID: 17384996
[TBL] [Abstract][Full Text] [Related]
12. Changes in bone volume and bone resorption by olpadronate treatment in an experimental model of uremic bone disease.
Tomat A; Gamba CA; Mandalunis P; De Grandi MC; Somoza J; Friedman S; Zeni S
J Musculoskelet Neuronal Interact; 2005 Jun; 5(2):174-81. PubMed ID: 15951635
[TBL] [Abstract][Full Text] [Related]
13. Adverse effects of hyperphosphatemia on myocardial hypertrophy, renal function, and bone in rats with renal failure.
Neves KR; Graciolli FG; dos Reis LM; Pasqualucci CA; Moysés RM; Jorgetti V
Kidney Int; 2004 Dec; 66(6):2237-44. PubMed ID: 15569312
[TBL] [Abstract][Full Text] [Related]
14. Irradiation alters the differentiation potential of bone marrow mesenchymal stem cells.
Wang Y; Zhu G; Wang J; Chen J
Mol Med Rep; 2016 Jan; 13(1):213-23. PubMed ID: 26572960
[TBL] [Abstract][Full Text] [Related]
15. Sevelamer hydrochloride attenuates kidney and cardiovascular calcifications in long-term experimental uremia.
Cozzolino M; Staniforth ME; Liapis H; Finch J; Burke SK; Dusso AS; Slatopolsky E
Kidney Int; 2003 Nov; 64(5):1653-61. PubMed ID: 14531797
[TBL] [Abstract][Full Text] [Related]
16. Direct inhibition of osteoblastic Wnt pathway by fibroblast growth factor 23 contributes to bone loss in chronic kidney disease.
Carrillo-López N; Panizo S; Alonso-Montes C; Román-García P; Rodríguez I; Martínez-Salgado C; Dusso AS; Naves M; Cannata-Andía JB
Kidney Int; 2016 Jul; 90(1):77-89. PubMed ID: 27165819
[TBL] [Abstract][Full Text] [Related]
17. The receptor activator of nuclear factor-kappaB ligand inhibitor osteoprotegerin is a bone-protective agent in a rat model of chronic renal insufficiency and hyperparathyroidism.
Padagas J; Colloton M; Shalhoub V; Kostenuik P; Morony S; Munyakazi L; Guo M; Gianneschi D; Shatzen E; Geng Z; Tan HL; Dunstan C; Lacey D; Martin D
Calcif Tissue Int; 2006 Jan; 78(1):35-44. PubMed ID: 16362459
[TBL] [Abstract][Full Text] [Related]
18. NPS R-568 halts or reverses osteitis fibrosa in uremic rats.
Wada M; Ishii H; Furuya Y; Fox J; Nemeth EF; Nagano N
Kidney Int; 1998 Feb; 53(2):448-53. PubMed ID: 9461105
[TBL] [Abstract][Full Text] [Related]
19. Accumulated uremic toxins attenuate bone mechanical properties in rats with chronic kidney disease.
Iwasaki Y; Kazama JJ; Yamato H; Shimoda H; Fukagawa M
Bone; 2013 Dec; 57(2):477-83. PubMed ID: 23920356
[TBL] [Abstract][Full Text] [Related]
20. Calcimimetic compound upregulates decreased calcium-sensing receptor expression level in parathyroid glands of rats with chronic renal insufficiency.
Mizobuchi M; Hatamura I; Ogata H; Saji F; Uda S; Shiizaki K; Sakaguchi T; Negi S; Kinugasa E; Koshikawa S; Akizawa T
J Am Soc Nephrol; 2004 Oct; 15(10):2579-87. PubMed ID: 15466262
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
